Relapsing polychondritis in a patient with suspected antiphospholipid syndrome presenting with inferior vena cava thrombosis: Palestinian case report Authors: Elias Amarneh, Alfarouq Alboom, Ghayda’ Sharif, Ayah Abulehia, Nour AlMaqadma Published: 2026 ABSTRACT BackgroundAntiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by arterial and venous thrombosis that commonly affects the deep veins of the lower extremities and cerebral vasculature. Inferior vena cava (IVC) thrombosis is an extremely rare manifestation of APS and is often associated with hypercoagulable states. Relapsing polychondritis (RPC) is an autoimmune disorder affecting cartilaginous structures, sometimes occurring alongside APS. However, the coexistence of primary suspected APS and RPC has rarely been reported.Case presentationA 33-year-old previously healthy male who presented with fever, acute right-sided flank pain, and systemic symptoms. Initial evaluation revealed urolithiasis, but persistent pain and elevated inflammatory markers prompted further imaging, which revealed IVC thrombosis.ConclusionThis case highlights the importance of recognizing suspected APS in patients presenting with unprovoked IVC thrombosis and highlights RPC as a potential autoimmune comorbidity. Although APS is a well-established prothrombotic disorder, its coexistence with RPC remains uncommon and poorly understood. The presence of antiphospholipid antibodies may contribute to the vascular inflammation observed in RPCs, suggesting a possible pathogenic link between these two conditions. Further studies are needed to explore the relationship between APS and RPC and refine diagnostic and therapeutic approaches. Background Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia caused by procoagulatory antibodies, most typically as a primary condition or associated with other diseases such as systemic lupus erythematosus (SLE). APS manifests with recurrent thrombotic events, and the deep veins of the lower extremities are the most frequent sites of thrombosis in APS, occurring in approximately 20–30% of patients according to large cohort studies [1, 2], whereas the cerebral vasculature is the most common site of arterial thrombosis in APS, typically presenting as a stroke or transient ischemic attack [1]. The exact cause remains unclear; however, the pathophysiology involves antiphospholipid antibodies that activate endothelial cells and platelets, leading to excessive production of tissue factor and thromboxane A2, both of which play crucial roles in disease progression [3, 4]. IVC thrombosis is a serious condition with multiple underlying causes. The most common cause is unretrieved IVC filters, reflecting both the increasing number of filter placements worldwide and the low retrieval rates. Other causes include congenital anomalies (such as IVC aneurysms), hypercoagulable states (e.g., thrombophilia, malignancy, pregnancy, and antiphospholipid syndrome), and abdominal trauma [5]. There is no clear clinical evidence about the correlation between APS and IVC thrombosis in the literature, except for a few case reports that mentioned co-occurrence. Relapsing polychondritis (RPC) is an immune-mediated systemic disease that affects cartilaginous tissue and organs rich in proteoglycans. The peak age of onset is between the ages of 40 and 50, but relapsing polychondritis may present at any age [1, 6]. The clinical features include intermittent inflammation of different cartilages, such as the articular and nasal regions; despite these being the most common, all cartilage types can potentially be affected. The pathogenesis behind RPC is not fully understood. However, it is believed to result from autoimmune-mediated inflammation and destruction of the cartilage [7], and it may be associated with other disorders in 30% of cases, including autoimmune connective tissue disease (SLE, systemic sclerosis, RA), ANCA-associated vasculitis, malignancy (myelodysplastic syndromes, solid organ cancers), other disorders (selective IgA deficiency) and APS [7, 8]. This case report aims to improve to the understanding of IVC thrombosis as an initial manifestation of suspected APS accompanied by RPC and to discuss the potential mechanisms involved. Case presentation A previously healthy 33-year-old male patient who was in his usual state of health with unlimited exercise tolerance started experiencing right-sided flank pain three days prior to admission. The pain had a gradual onset, was stabbing in nature, was continuous, severely increased in intensity, and radiated to the back. There were no identifiable factors that exacerbated or relieved the pain. He sought medical advice at an outpatient clinic, where he was diagnosed with urolithiasis and discharged with prescribed analgesics. However, the prescribed analgesics did not relieve the pain, which worsened over the next two days, prompting him to return to the emergency room on the 7th of July 2023. Upon admission, he presented with the same characteristics of flank pain. In addition to the pain, he reported a fever of 39 °C, nausea, and vomiting of the gastric contents twice in minimal amounts. He also experienced an occipitofrontal headache, dizziness, and arthralgia, primarily affecting the lower back and large joints in both the upper and lower extremities. These symptoms were all new and had not been experienced previously. The event was not preceded by trauma or any abnormal activity. The patient denied any history of weight loss, loss of appetite, decreased activity, leg swelling or discoloration, superficial vein swelling, pitting edema, hematuria, dysuria, ocular involvement, photosensitivity, chest pain, dyspnea, cardiac symptoms, epigastric pain, confusion, seizures, small joint pain, joint malformation, rheumatoid nodules, or dryness in the eyes or mouth. There was no history of recent surgery, immobilization, or previous deep vein thrombosis (DVT), and the patient denied any family history of thrombophilia. Upon arrival, the patient had diffuse generalized abdominal tenderness, with the greatest intensity in the right upper quadrant, and was otherwise free. His vital signs were consistent with fever at 39 °C, 135/84 mmHg, 98% O2 saturation, and a heart rate of 65 BPM. The laboratory findings revealed increased inflammatory markers (ESR, CRP) (68, 49.3), fibrinogen (500), PTT (58.9), lactic acid (16.5), thrombocytopenia (54000), and normal PT and INR (13.4, 1.08), all of which raised suspicion for a vascular event, suggesting that CT angiography should be used for further evaluation. Abdominal CT angiography revealed a filling defect in the inferior vena cava (IVC) (Fig. 1), suggesting IVC thrombosis, without the presence of free fluid in the abdomen or pelvis. Additionally, bilateral pathologically enlarged iliac lymph nodes were observed, with the largest measuring 1.5 cm in the short axis on the right side. Otherwise, it is unremarkable. Fig. 1A-C: CT angiography showing a filling defect in the inferior vena cava, consistent with IVC thrombosis. (A) Axial view, (B) sagittal view, (C) coronal view A-C: CT angiography showing a filling defect in the inferior vena cava, consistent with IVC thrombosis. (A) Axial view, (B) sagittal view, (C) coronal view Because of the suspected hypercoagulable status, contrast-enhanced CT scans of the head, neck, and chest were performed to rule out other thrombotic events, revealing no significant abnormalities. Abdominal and pelvic imaging revealed no masses or infectious focus. The laboratory workup included testing for coagulation profile, autoantibodies, and complement levels. The results were positive for lupus anticoagulant, anticardiolipin, anti-beta-2 glycoprotein, and antinuclear antibodies, with further details provided in (Table 1). However, the serum levels of C3 and C4 were normal, and the urinalysis was unremarkable. Serologies for HBV and HCV were nonreactive, and cryoglobulin was negative. Additionally, glucose, total cholesterol, and cholesterol fractions were all within normal limits. Table 1Autoantibody and coagulation profile resultsTestResultsANAAPositive (1:320)Lupus anticoagulantPositiveAnticardiolipinPositiveAnti-beta-2-glycoprotein 1PositiveAPLAB IgGCPositiveP-ANCADNegativeC3ENormalC4 FNormalDirect Coombs testNegativeIndirect Coombs testNegativeUrinalysisNo proteinuriaAANA: Antinuclear Antibodies, BAPLA: Antiphospholipid Antibodies, CIgG: Immunoglobulin GDP-ANCA: Perinuclear Anti-Neutrophil Cytoplasmic Antibodies, E C3: Complement 3, FC4: Complement 4 Table 1Autoantibody and coagulation profile resultsTestResultsANAAPositive (1:320)Lupus anticoagulantPositiveAnticardiolipinPositiveAnti-beta-2-glycoprotein 1PositiveAPLAB IgGCPositiveP-ANCADNegativeC3ENormalC4 FNormalDirect Coombs testNegativeIndirect Coombs testNegativeUrinalysisNo proteinuriaAANA: Antinuclear Antibodies, BAPLA: Antiphospholipid Antibodies, CIgG: Immunoglobulin GDP-ANCA: Perinuclear Anti-Neutrophil Cytoplasmic Antibodies, E C3: Complement 3, FC4: Complement 4 Autoantibody and coagulation profile results AANA: Antinuclear Antibodies, BAPLA: Antiphospholipid Antibodies, CIgG: Immunoglobulin G DP-ANCA: Perinuclear Anti-Neutrophil Cytoplasmic Antibodies, E C3: Complement 3, FC4: Complement 4 An echocardiogram was performed, and the results were unremarkable. Likewise, the ABG findings were normal. A blood film revealed microcytic RBCs, thrombocytopenia (platelets 54,000/µL) with normal-sized and normally shaped platelets, and leukocytosis (WBCs 17,000/µL) with reactive inflammatory cells. No blast cells were observed. Although leukocytosis was present, the absence of microbiological evidence, negative blood cultures, and lack of an identifiable infectious focus on imaging made an infectious etiology unlikely. The observed thrombocytopenia was interpreted as a clinical manifestation of suspected APS; other potential etiologies, such as disseminated intravascular coagulation (DIC) and heparin-induced thrombocytopenia (HIT), were not clinically suspected based on the overall presentation and the patient’s clinical course. On the third day of hospitalization, the patient developed painful, scaly, purpuric, and ecchymotic rashes over his pinna and the posterior triangle of his neck (Fig. 2). Additionally, the patient exhibited swollen and tender nasal cartilage. Relapsing polychondritis was suspected. For management, corticosteroids were initiated because of acute inflammatory symptoms. The patient received pulse intravenous methylprednisolone (1 g bolus per day for five consecutive days). The erythema, pain, and swelling of the affected areas responded well to steroid treatment, confirming the diagnosis of RPC on the basis of the modified Damini criteria. Fig. 2A-D: (A) Scaly purpuric rash affecting the right cartilaginous pinna. (B) Bilateral involvement of cartilaginous pinna with ecchymosis and scaling. (C) Purpuric and ecchymotic rash over the posterior triangle of the neck. (D) Visible swelling and erythema of the nasal cartilage A-D: (A) Scaly purpuric rash affecting the right cartilaginous pinna. (B) Bilateral involvement of cartilaginous pinna with ecchymosis and scaling. (C) Purpuric and ecchymotic rash over the posterior triangle of the neck. (D) Visible swelling and erythema of the nasal cartilage On the basis of the patient’s clinical presentation, laboratory findings, and imaging results, along with the absence of clear clinical manifestations of other autoimmune disorders that would meet their diagnostic criteria, the patient was initially diagnosed with suspected APS complicated by IVC thrombosis. He was also clinically diagnosed with RPC according to the modified Damini criteria, as his RPC symptoms responded to steroids, marking it as the first manifestation of the disease. He was started on warfarin 5 mg once daily, bridged with enoxaparin 60 mg subcutaneously twice daily, aiming for a target international normalized ratio (INR) in the range of 2–3. Surgical intervention was not performed on this patient, and thrombolytic agents for the dissolution of the IVC thrombus were not given. At discharge, the patient was clinically stable and prescribed maintenance therapy with hydroxychloroquine 200 mg orally once daily. Oral prednisone 60 mg once daily was continued for two weeks, followed by gradual tapering by 5 mg per week according to clinical response. For gastric protection, esomeprazole 40 mg orally once daily was prescribed. The patient was instructed to continue warfarin 7.5 mg daily with close INR monitoring and dose adjustment as required. He was advised to repeat laboratory investigations, including INR and liver function tests (ALT and AST), and to attend a follow-up visit after three days with the results. Unfortunately, the patient was subsequently lost to follow-up. Discussion APS is an autoimmune disorder characterized by arterial and venous thromboembolic events and pregnancy morbidity in the presence of antiphospholipid antibodies, with a prevalence of 40–50 per 100,000 individuals [9]. APS pathophysiology is not well understood, but there are proposed mechanisms that begin with the formation of procoagulatory antibodies by B cells. These antibodies bind to anticoagulant proteins (e.g., protein C, protein S, antithrombin III), forming antigen‒antibody complexes, which results in inactivation; on the other hand, these antibodies activate inflammatory cells, vascular endothelial cells and platelets and overexpress β2-glycoprotein I, GpIIbIIIa and vascular endothelial growth factor, resulting in increased platelet adherence and aggregation, inducing a hypercoagulable state and increasing the risk of thrombosis and embolism [10, 11]. Antiphospholipid syndrome (APS) should be considered and tested in patients who present with unprovoked venous thromboembolism (VTE) at age 45 or younger, as well as in those with a history of recurrent VTE affecting any organ. It should also be considered in patients with thrombosis in unusual vascular beds or with arterial thrombosis. The deep veins of the lower extremities are the most commonly affected sites of thrombosis in APS, occurring in approximately 20 to 30% of patients, according to large cohort studies [1, 2]. Moreover, the cerebral vasculature is the most frequent site of arterial thrombosis, typically presenting as a stroke or transient ischemic attack in APS patients [1]. Although there are no universally established diagnostic criteria for antiphospholipid syndrome (APS), the clinical presentation plays a crucial role in making the diagnosis. APS is typically diagnosed when characteristic clinical features are present, along with one or more antiphospholipid (aPL) antibodies, such as anticardiolipin antibodies (aCLs; IgG or IgM), anti-beta2 glycoprotein I antibodies (anti-beta 2 GPI; IgG or IgM), or lupus anticoagulant (LA). APL results are considered positive when the levels are moderate to high, typically exceeding 40 times the upper limit of normal. The diagnostic probability increases when two or more clinically significant and persistent aPL findings are observed, particularly if both anti-beta 2 GPI and aCL antibodies are of the IgG type [10, 12]. Additional supportive features, such as heart valve disease, unexplained thrombocytopenia, or kidney involvement (aPL nephropathy), further strengthen the diagnosis. It is also essential to rule out other causes of thrombosis or pregnancy complications to definitively establish the diagnosis of APS [10, 13]. In our patient, the clinical presentation of unprovoked thrombosis in the inferior vena cava (IVC) at the age of 33 years, coupled with positive antiphospholipid antibodies and thrombocytopenia without any history suggestive of other autoimmune diseases, such as systemic lupus erythematosus (SLE), led to the establishment of the suspected APS diagnosis. However, it is important to acknowledge that a definitive diagnosis of APS requires persistent antibody positivity confirmed by repeat testing after at least 12 weeks. Since our patient was lost to follow-up and repeat testing was not documented, the condition is more accurately described as suspected APS rather than a definitive diagnosis. Patients with SLE were excluded despite being positive for ANA, as they did not meet the diagnostic criteria [10]. IVC thrombosis is considered an unusual site for thrombosis, and in such cases, ruling out both hereditary and acquired thrombophilia is essential [5]. In this case, a thorough workup confirmed the presence of antiphospholipid antibodies, supporting the diagnosis of suspected APS. Relapsing polychondritis is a rare autoimmune disease with various systemic clinical manifestations due to cartilage inflammation throughout the body. The most common sites affected were the ears, joints, and nasal cartilage, with frequencies of presenting symptoms of 43%, 32%, and 21%, respectively [3]. Other manifestations include vasculitis, inflammation of the laryngotracheal tree, heart valves, scleritis, polyarthritis, neurosensory hearing loss, and skin lesions, which can include purpura, erythema nodosum, erythema multiforme, and panniculitis [7]. Very few cases of RPC associated with APS have been reported, especially with APS being primary rather than secondary to SLE. Most likely, these disorders precede the onset of RPC, but in some cases, RPC can accompany the underlying disease presentation, as in our case [14]. A review of the limited published literature reveals both similarities and differences among reported cases. Common features include the presence of anti-phospholipid antibodies in patients with RPC and the potential for severe, life-threatening thrombotic events such as Budd-Chiari syndrome [15]. However, notable differences exist in the clinical context and disease associations. For example, one reported case described a patient with ankylosing spondylitis who developed RPC, APS, and myelodysplastic syndrome, with successful response to baricitinib [16]. Another case involved APS secondary to systemic lupus erythematosus coexisting with RPC [17], whereas our patient had primary APS without evidence of SLE. These variations suggest that the APS-RPC association may occur across different autoimmune backgrounds, and the presence of cartilaginous inflammation in a patient with thrombotic events should raise suspicion for this overlap syndrome regardless of whether APS is primary or secondary [14]. Our patient presented with small ecchymotic lesions over his neck and ears, which may have been secondary to RPC-associated vasculitis. Other systemic vasculitis conditions were excluded through an extensive workup, as RPC can sometimes be associated with other forms of systemic vasculitis. RPC is challenging to diagnose because of the absence of a single reliable diagnostic laboratory test. The diagnosis is based on the presence of a sufficient number of key clinical features. A biopsy is typically reserved for patients with atypical presentations or for patients who are unresponsive to therapy [3]. Two criteria are used to diagnose RP: the McAdam criteria, which require 3 or more of the following mentioned items: auricular chondritis, nasal chondritis, respiratory tract chondritis, nonerosive seronegative inflammatory polyarthritis, ocular inflammation, or audiovestibular damage; and the Damiani and Levani criteria, which require one of the following mentioned items: three or more McAdam criteria, two or more McAdam criteria with a response to steroids and/or Dapson criteria, or one or more McAdam criteria with positive histology on biopsy [18]. In our case, we relied on the Damiani and Levani criteria, as the patient had auricular and nasal chondritis and responded well to steroids as the lesions disappeared [2]. However, it is important to acknowledge the limitations of diagnosing RPC based solely on clinical criteria in the absence of histopathological confirmation. Although cartilage biopsy can support the diagnosis, it is not mandatory in patients with a typical presentation [2, 18]. Invasive biopsy procedures may yield nonspecific inflammatory findings and are generally reserved for atypical, diagnostically uncertain, or treatment-resistant cases. In our patient, while histopathological confirmation was not pursued, the presence of characteristic auricular and nasal chondritis together with a rapid and marked response to corticosteroid therapy provided strong clinical support for the diagnosis. The development of RPC in patients with APS has rarely been reported. There are a few published case reports that mention the coexistence of both diseases, although this association is most commonly observed in the context of SLE. The literature does not currently provide sufficient evidence to support primary APS and RPC correlation. However, some hypotheses suggest the role of antiphospholipid antibodies with RPs. Moreover, in the absence of SLE, there remains a potential overlap between primary APS and other autoimmune diseases [14, 19]. Our patient developed ear chondritis and nasal cartilage inflammation, along with small ecchymotic lesions over his neck and ear. Although the coexistence of RPC and primary APS could be interpreted as coincidental given the rarity of both disorders, accumulating evidence suggests that this association may reflect shared immune dysregulation rather than random overlap. Several case reports have documented the co-occurrence of APS and RPC in the same individual [14, 19], and repeated observation argues against pure coincidence. Both conditions are characterized by B-cell hyperactivity, autoantibody production, immune complex–mediated inflammation, complement activation, and endothelial injury. In APS, antibodies against β2-glycoprotein I promote endothelial dysfunction and a prothrombotic state [8, 10], whereas in RPC, immune-mediated cartilage destruction involves autoimmunity to type II collagen and complement-driven inflammation. These overlapping mechanisms provide a biologically plausible link between the two diseases. Although no single shared genetic mutation has been identified, both disorders demonstrate autoimmune clustering and associations with MHC class II alleles, supporting the hypothesis of a common autoimmune-prone genetic background. Accordingly, this case underscores the importance of maintaining a high index of suspicion for overlapping autoimmune syndromes when patients present with atypical combinations of thrombotic and inflammatory manifestations [8, 10]. The management of IVC thrombosis varies according to the etiology and clinical presentation of the patient, including medical therapy with anticoagulants, such as low-molecular-weight heparin; indirect factor X inhibitors, such as foundaparinux; and surgical therapy, including endovascular thrombolytic injection or stent placement and thrombectomy [5]. After the patient was diagnosed with IVC thrombosis, therapeutic enoxaparin was initiated, along with warfarin bridging, to reach an international normalized ratio (INR) of 2–3. The patient was also started on pulse intravenous methylprednisolone (1 g bolus per day for five consecutive days). Inflammatory markers and platelet count started to improve gradually. By the second day of the methylprednisolone regimen, ear swelling, pain, and skin lesions had dramatically improved (Fig. 3) [20, 21]. Fig. 3A-C: Relapsing polychondritis post treatment: (A), (B) Resolution of the purpuric and ecchymotic ears and neck lesions, (C) fading of nasal cartilage swelling and erythema A-C: Relapsing polychondritis post treatment: (A), (B) Resolution of the purpuric and ecchymotic ears and neck lesions, (C) fading of nasal cartilage swelling and erythema The patient was discharged on oral prednisone (1 mg/kg/day) with gradual tapering along with warfarin (7.5 mg). Although close follow-up was planned, the patient never returned for scheduled visits and was lost to follow-up. Conclusion This case report addresses the diagnostic challenges faced in a patient with APS who presented with RPC, particularly IVC thrombosis. This underscores the importance of adopting a systematic approach to accurately diagnose and administer appropriate treatment in such rare cases. Moreover, further studies are needed to explore the coexistence of APS and RPC to establish more effective diagnostic criteria and treatment guidelines. Furthermore, we highlight the diagnostic and therapeutic challenges associated with the coexistence of primary antiphospholipid syndrome and relapsing polychondritis. The key clinical message is that atypical thrombotic events followed by inflammatory cartilaginous manifestations should prompt evaluation for underlying autoimmune overlap syndromes. Although the coexistence of APS and RPC may be rare, the possibility of shared autoimmune predisposition rather than pure coincidence should be considered. Further studies are required to better understand the immunogenetic basis and clinical implications of this association.